Current studies aim at comparative and summative evaluation of different methods, with Japan and other countries [46,47] implementing simultaneous determination of PIVKA II and AFP as a screening method to monitor patients at high risk of developing hepatocellular carcinoma [48]. This evidence concerns the gene AFP and hepatocellular carcinoma.